IPSEN (IPSEY) Expected to Release Earnings on Thursday

IPSEN (OTCMKTS:IPSEY) is anticipated to release its resultson Thursday, July 30th. Analysts expect the company to post earnings of $1.86 per share and revenue of $2.4202 billion for the quarter.

IPSEN Stock Up 6.9%

IPSEY stock opened at $47.11 on Thursday. The company has a 50 day moving average price of $46.32 and a two-hundred day moving average price of $45.08. IPSEN has a one year low of $30.05 and a one year high of $51.10.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. HC Wainwright restated a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Finally, Zacks Research raised shares of IPSEN to a “hold” rating in a research note on Friday, May 29th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, IPSEN currently has an average rating of “Hold”.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).